TheraRadar
← Back
Data updated: May 30, 2026

MALLINCKRODT INC

Pharma
RespiratoryImmunologyGastroenterology Execution: Good

MALLINCKRODT INC is a pharmaceutical company focused on Respiratory, Immunology, Gastroenterology. Key products include XARTEMIS XR.

1947
Since
35
Drugs
-
Trials
0
New Drugs (2yr)
Modality:

MALLINCKRODT INC at a Glance

  • Fast trial execution (23 months median completion)

MALLINCKRODT INC's Key Drugs

MALLINCKRODT INC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

MALLINCKRODT INC's Recent FDA Approvals

New NDA/BLA approvals for MALLINCKRODT INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MALLINCKRODT INC's Therapeutic Areas

MALLINCKRODT INC's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Immunology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 27%
0 drugs Phase 3: 3 Phase 1: 1
Immunology 27%
0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 3
Gastroenterology 16%
0 drugs Phase 3: 1 Phase 2: 1 Phase 1: 2
Cardiovascular 16%
0 drugs Phase 3: 2
Dermatology 14%
0 drugs Phase 3: 1 Phase 2: 1 Phase 1: 1

MALLINCKRODT INC Pipeline Snapshot

MALLINCKRODT INC has 19 active clinical programs from ClinicalTrials.gov — 9 Phase 3, 3 Phase 2 and 7 Phase 1.

9
Phase 3
3
Phase 2
7
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Respiratory pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 3/3 completed
  • • Speed: 23 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges